Company Overview of Aptalis Pharma Canada Inc.
Aptalis Pharma Canada Inc. develops therapies for cystic fibrosis and gastrointestinal disorders in the United States, the European Union, and Canada. It manufactures and commercializes pharmaceutical products, including ZENPEP, ULTRASE, and VIOKASE products for the treatment of exocrine pancreatic insufficiency (EPI); PANZYTRAT for use in the treatment of EPI and pancreatic enzyme deficiency; CANASA for the treatment of ulcerative proctitis; and SALOFALK for the treatment of inflammatory bowel diseases, such as ulcerative colitis, ulcerative proctitis, and Crohn’s disease. The company was incorporated in 2007 and is based in Mont-Saint-Hilaire, Canada. Aptalis Pharma Canada Inc. operates as...
597 Bd Sir Wilfrid Laurier
Mont-Saint-Hilaire, QC J3H 4X8
Founded in 2007
Key Executives for Aptalis Pharma Canada Inc.
Aptalis Pharma Canada Inc. does not have any Key Executives recorded.
Aptalis Pharma Canada Inc. Key Developments
Aptalis Pharmaceutical Technologies Presents at BIO-Europe Spring 2015, Mar-10-2015 03:00 PM
Jan 29 15
Aptalis Pharmaceutical Technologies Presents at BIO-Europe Spring 2015, Mar-10-2015 03:00 PM. Venue: Paris Expo - Porte de Versailles, Hall 5, Paris, France.
Aptalis Pharmaceutical Technologies Presents at 8th Annual BIO Europe Spring 2014, Mar-11-2014 02:30 PM
Jan 21 14
Aptalis Pharmaceutical Technologies Presents at 8th Annual BIO Europe Spring 2014, Mar-11-2014 02:30 PM. Venue: OVAL Lingotto, Turin, Italy.
Aptalis Pharma Inc., Forest Laboratories Inc. - M&A Call
Jan 8 14
To discuss the agreement to acquire Aptalis
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries